IQVIA, a leading global provider of clinical research services and healthcare intelligence, has announced a strategic collaboration with SCRI Development Innovations, the contract research arm of Sarah Cannon Research Institute. This partnership aims to transform oncology clinical trials globally by enhancing trial processes, eliminating operational barriers, accelerating data delivery, and expediting patient access to cutting-edge cancer therapies.
The collaboration leverages the complementary strengths of both organizations to create a more streamlined approach to oncology research. IQVIA brings its extensive global footprint and precision in managing one in five oncology trials in the United States, along with advanced capabilities in data integration, technology, and analytics. SCRI Development Innovations contributes its deep community oncology expertise and innovative Accelero operational model.
Accelerating Trial Delivery Through Innovation
The Accelero model developed by SCRI represents a significant advancement in clinical trial operations. It expedites trial activation, enhances site-level recruitment, and seamlessly integrates electronic health record data with electronic data capture systems across U.S. trial sites. This integration streamlines data collection and reduces the administrative burden on research sites.
Richard Staub, President of Research & Development Solutions at IQVIA, emphasized the strategic value of the partnership: "This collaboration embodies our commitment to innovation, efficiency and delivering superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide."
Addressing Key Challenges in Oncology Research
The partnership addresses several persistent challenges in oncology clinical trials, including operational inefficiencies, data collection bottlenecks, and the complexity of managing multiple vendors. By creating a unified delivery model, the collaboration aims to simplify trial execution while maintaining high-quality standards.
Dee Anna Smith, Chief Executive Officer at Sarah Cannon Research Institute, highlighted the operational benefits: "Through our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrollment and expedite data delivery through our cutting-edge technology solutions. Additionally, we will leverage IQVIA's global reach, expertise and capabilities in trial design and recruitment to provide a seamless global delivery model for our partners."
Expanding Global Access to Innovative Cancer Treatments
The collaboration is expected to have significant implications for cancer research globally. By combining IQVIA's international presence with SCRI's specialized oncology expertise, the partnership aims to expand access to clinical trials across diverse patient populations and geographic regions.
SCRI brings substantial experience to the partnership, having conducted more than 850 first-in-human clinical trials since its inception. The organization has contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. Its research network encompasses more than 1,300 physicians actively enrolling patients in clinical trials at over 250 locations across 24 U.S. states.
Industry Impact and Future Directions
This strategic alliance represents a significant development in the oncology clinical research landscape. By integrating complementary capabilities, the partnership aims to accelerate the development timeline for new cancer therapies while maintaining rigorous scientific standards.
The collaboration was announced ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. Industry professionals attending the conference can learn more about the partnership by visiting IQVIA at Booth 14103 or SCRI at Booth 27022.
As the demand for innovative cancer treatments continues to grow, partnerships that enhance the efficiency and effectiveness of clinical trials will play an increasingly important role in advancing oncology research and improving patient outcomes worldwide.
